Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies

OBJECTIVES: In two Phase III studies, lisdexamfetamine dimesylate (LDX) reduced binge eating (BE) days/week in adults with moderate to severe binge eating disorder (BED) and was associated with improvement based on the Clinical Global Impressions–Improvement (CGI-I) scale. In this study, post hoc an...

Descripción completa

Detalles Bibliográficos
Autores principales: Citrome, Leslie, Kando, Judith C, Bliss, Caleb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819587/
https://www.ncbi.nlm.nih.gov/pubmed/29497297
http://dx.doi.org/10.2147/NDT.S158395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819587/
https://www.ncbi.nlm.nih.gov/pubmed/29497297
http://dx.doi.org/10.2147/NDT.S158395

Ejemplares similares